Biocon Biologics is leading the global biosimilars revolution. By giving patients around the world access to affordable life-saving therapies, we are driving innovation in biologics, expanding treatment options, and putting equity back into healthcare.
Transforming Healthcare. Transforming Lives.
From lab to market, we are a fully integrated, global biosimilars enterprise
From lab to market
A fully integrated, global biosimilars enterprise
Science
We lead with pioneering R&D, innovative tech platforms, exceptional talent and global scale manufacturing.
Products
We are addressing unmet medical needs and improving healthcare outcomes for patients in 120+ countries around the world.
Our Key Milestones
Launched Yesintek™ (bUstekinumab), a biosimilar to Stelara®, in the U.S.
Biocon Biologics consolidates acquired business operations across 120+ countries, and surpasses the USD 1 billion annual revenue mark.
Biocon Biologics successfully completes its multi billion-dollar acquisition of Viatris’ global biosimilars business.
Semglee, biosimilar Insulin Glargine, receives a historic U.S. approval as the world’s first ‘interchangeable’ biosimilar product.
Biocon’s Biosimilars business is consolidated under an independent entity – Biocon Biologics Limited – with its dedicated management.
Fulphila becomes the first biosimilar Pegfilgrastim to be approved in the U.S.
Responsibility
We are committed to making a positive and lasting impact on the world by standing firmly behind our ESG principles. Focusing on patient, people, environment, social and stakeholder equity, we strive to build a more inclusive, healthy and sustainable future for all.
On X
;
Biocon Biologics was named the Captis Pharmacy Supplier of the Year at the recent Captis Conference. Captis is a collaborative healthcare organization with 90+ health systems working together to increase efficiencies and reduce expenses by aggregating spend and redesigning supply…
We’re proud to share that Akhilesh Nand, Global Head – GRC (Governance, Risk, Compliance) & Company Secretary, Biocon Biologics, has been named ‘The Great Indian Governance Icon 2025’ by Transformance Forums.
This prestigious honor celebrates India's top governance leaders who…
#Press: Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a #PatientAssistance Program (PAP) in #Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved…
#FromWomentoWomen
At Biocon Biologics, we are dedicated towards creating affordable & accesible healthcare solutions for people worldwide.
However, for some, like Rhonda, our Chief Operating Officer, it becomes deeply personal. Watch to know why she is driven to create…
#BioconBiologics at #NCCM2025
Dr. Rahul Kapur, Head of Medical Affairs, Emerging Markets at Biocon Biologics, will be speaking at the National Cancer Congress Malaysia (NCCM) 2025 on the topic: “Value-Based Care and the Impact of Biosimilars.”
Dr. Kapur shares insights on how…
As we continue our efforts to broaden access to high-quality biosimilars across Canada, we look forward to connecting with Québec’s dynamic life sciences community. Looking forward to more meaningful collaboration with local innovators, researchers, and healthcare leaders to…
